Ketamine vs ECT: Choosing a Therapy for Resistant Depression

You've tried the antidepressants. Maybe three, maybe five, maybe more. Each time, you waited weeks for relief that never quite arrived. Now you're weighing two options that sound more specialized: ketamine therapy or electroconvulsive therapy (ECT). You're not sure which one is right for you, and the research you've found so far seems contradictory.

Roughly one in three people with depression don't respond to standard antidepressants, so reaching this crossroads in treatment-resistant depression is more common than most people realize.

The bottom line: Current evidence suggests ketamine can work as well as ECT for many outpatients with non-psychotic treatment-resistant depression, often with fewer cognitive side effects. ECT may be a better fit if your depression is very severe, includes psychotic features, or requires inpatient care.

The right choice depends on your specific situation. The results make more sense once you look at who was studied and how treatment was delivered.

What Is ECT?

Electroconvulsive therapy is a medical procedure that uses a controlled electrical current to trigger a brief seizure in the brain. It's one of the oldest and most studied treatments for severe depression.

The name sounds alarming. The reality is different from what most people picture. You're under general anesthesia the entire time. Muscle relaxants prevent visible convulsions. The seizure itself lasts less than 60 seconds, and you won't remember the procedure when you wake up.

A typical ECT course involves six to twelve sessions, scheduled two to three times per week over three to four weeks. That can take over your week for a while, especially if you're already running on empty. Many people notice improvement after about six treatments, though some respond even sooner. ECT is FDA-cleared for severe depressive episodes in people 13 and older.

Response rates are strong. Studies show 70 to 80% of people with treatment-resistant depression respond to ECT, and 50 to 60% achieve full remission.

What Is Ketamine Therapy?

Ketamine therapy uses a medication originally developed as an anesthetic to produce rapid antidepressant effects. It works through an entirely different brain system than standard antidepressants like SSRIs and SNRIs, which is one reason it can help when those medications haven't.

Where traditional antidepressants gradually adjust serotonin or norepinephrine levels, ketamine works on the glutamate system. Think of it as helping your brain build new connections, almost like clearing paths through an overgrown forest. That glutamate-based mechanism explains its most notable feature: speed. Many people notice a shift within days, not weeks.

Forms of Treatment

Ketamine therapy comes in several forms. IV infusions run about 40 minutes in a clinic. Esketamine (Spravato) is an FDA-approved spray for treatment-resistant depression, which patients self-administer under clinical supervision. Sublingual tablets dissolve under the tongue, sometimes taken at home with telehealth oversight.

A standard IV course is six infusions over two to three weeks. Response rates range from 50 to 70 percent in people with treatment-resistant depression.

A Note on FDA Approval

Ketamine use for depression is off-label. The FDA has approved ketamine as an anesthetic, not specifically for psychiatric conditions, though it has approved esketamine for treatment-resistant depression.

What the Head-to-Head Research Shows

If the research has felt contradictory, you're not imagining it. A lot comes down to which patients each trial enrolled and how clinicians delivered treatment.

The ELEKT-D Trial

The biggest study comparing these two treatments is the ELEKT-D trial, published in the New England Journal of Medicine in 2023. It randomized 403 people across five U.S. sites and found that ketamine was at least as effective as ECT for non-psychotic treatment-resistant depression.

In that trial, 55.4% of people receiving ketamine responded, compared to 41.2% receiving ECT. Remission rates were 37.9% for ketamine versus 21.8% for ECT.

Why the Results Vary

Most of the confusion in this literature comes from who was actually studied. About 90% of ELEKT-D participants were outpatients, less severe than people who'd been hospitalized. A Swedish trial called KetECT, which enrolled hospitalized people, found that ECT outperformed ketamine in that group, with response rates of 71% versus 57%.

That explains why these studies can seem to point in different directions. A 2024 analysis of the ELEKT-D data, published in JAMA Network Open, sharpened the picture. Among outpatients with moderate-to-severe treatment-resistant depression, ketamine produced greater improvement than ECT.

For people with very severe pretreatment depression, ECT showed an earlier advantage, though scores were similar between groups by the end of treatment. Severity and setting matter more than picking an outright winner.

What This Means in Practice

If you need relief quickly, ketamine acts sooner. Both treatments also reduce suicidal thoughts, and ketamine's effects on those thoughts can begin within hours. If you're dealing with a more severe case and complete a full treatment course, ECT may produce greater overall improvement.

Both treatments share a similar limitation: neither one usually provides lasting relief without ongoing care. Of those who achieved remission in follow-up data, roughly 63% of the ECT group and 70% of the ketamine group eventually relapsed.

Ketamine vs ECT at a Glance

Memory Loss and Other Side Effects

For many people, memory is the deciding factor. That's a reasonable concern. The two treatments affect cognition in fundamentally different ways.

Memory Effects

ECT's most significant side effect is memory loss. A majority of people report some memory problems after treatment, and for a meaningful share, those problems last weeks to years. The memories most often affected are autobiographical ones: personal life events, particularly from the months before treatment.

Most people see improvement by six months after their last session, but some gaps may never return. ECT can also temporarily affect your ability to learn new information, drive, work, or manage finances.

Ketamine's cognitive effects are different in kind, not just degree. During a session, you'll likely experience dissociation: a temporary feeling of detachment from your body or surroundings. Some people describe floating sensations, visual changes, or a dreamlike state. These effects typically resolve within hours. At therapeutic doses, cognition often remains stable or improves over the course of treatment.

The ELEKT-D trial captured this difference clearly. Memory recall scores declined by just 0.9 points in the ketamine group, compared to 9.7 points in the ECT group.

Other Side Effects

Beyond memory, both treatments carry other side effects. ECT commonly causes post-session headache, nausea, fatigue, and temporary confusion. Ketamine's most common effects are nausea, dizziness, elevated blood pressure, and drowsiness, all of which tend to be mild to moderate and resolve the same day. A meta-analysis found ketamine had significantly lower rates of muscle pain, while ECT had lower rates of dissociation and blurred vision.

For more on safety at therapeutic doses, see our ketamine safety overview.

Logistics and Daily Life

How treatment fits into real life matters, especially when you're already depleted.

ECT requires general anesthesia at every session. In practical terms, that usually means a hospital or specialized clinic, a companion to bring you and take you home, and realistic limits on work and daily tasks during the acute phase. Two to three sessions per week for three to four weeks creates a significant scheduling demand.

Ketamine sessions are shorter. IV infusions last about 40 minutes, with roughly two hours total for the visit. These sessions don't require general anesthesia, though you'll still need someone to drive you and should avoid important tasks on treatment days.

At-home sublingual ketamine reshapes the practical equation. No hospital trips, no anesthesia, no companion needed for each appointment. Sessions happen in your own space, with telehealth clinical oversight, and the schedule can be more flexible.

For someone already exhausted and coordinating other medical care, this difference can be substantial. Neither treatment lets you drive on treatment days.

Cost and Insurance

Insurance often shapes this decision as much as clinical evidence does. That may not feel fair, but it's real for most people.

Medicare, Medicaid, and most private insurers broadly cover ECT and Spravato. IV ketamine rarely qualifies for coverage because the use is off-label. Select insurance partners cover sublingual ketamine, which is also off-label and compounded, through programs like Innerwell.

For someone paying entirely out of pocket, at-home sublingual programs or IV ketamine infusions cost less upfront than a full ECT course. For someone with insurance, ECT and Spravato may be the most affordable paths because coverage dramatically reduces what you pay.

Which Treatment May Be Right for You

You don't have to guess your way through this decision. In most cases, it comes down to setting, symptom severity, and what tradeoffs feel acceptable to you.

When Ketamine Fits

Consider ketamine if you're an outpatient with non-psychotic depression severe enough to need another option, if memory side effects are a primary concern, if you need rapid relief, or if you strongly prefer to avoid general anesthesia.

The ELEKT-D data supports ketamine as a reasonable first option in these circumstances. If you're unsure whether you're a good candidate for ketamine, an initial screening can answer that for you.

When ECT Fits

Consider ECT if your depression includes psychotic features (hallucinations or delusions), if you're hospitalized or have very severe symptoms including acute suicidal thoughts, or if you have catatonia.

If You've Tried One Already

If you've already tried ketamine without adequate response, ECT may also make sense. ECT has particularly strong evidence for older adults when combined with medication for relapse prevention.

Clinical research suggests that ketamine can help even when ECT hasn't worked, and vice versa. Some treatment programs use them in sequence: ketamine first, then ECT if needed.

How Innerwell's At-Home Ketamine Therapy Works

If you're leaning toward ketamine, the practical questions usually come next: how treatment works at home, who oversees it, and what kind of support is built in.

The medication is only part of what makes ketamine work. Ketamine creates a window of neuroplasticity, your brain's ability to form new connections. Ketamine opens a door; talk therapy helps you walk through it.

One study found that combining ketamine with cognitive therapy extended the median time to relapse to 12 weeks, compared to the roughly one week that a single ketamine dose provides on its own.

This isn't ketamine dropped off with minimal supervision. Innerwell's clinical team includes licensed psychiatric providers and Master's- and Doctoral-level licensed therapists. The program pairs at-home sublingual ketamine tablets with preparation and integration therapy, telehealth monitoring, and ongoing support throughout treatment.

The process:

1. Evaluation: An initial psychiatric evaluation reviews your history, current medications, past treatment responses, and candidacy, then develops your treatment plan.
2. Delivery: A licensed pharmacy ships sublingual ketamine tablets to your home, with dosing instructions and clinical support built in. No IV clinics, no general anesthesia, no two-hour post-dose observation requirements.
3. Preparation and integration: Therapy sessions before treatment focus on intention-setting. Sessions afterward give you space to process the experience, address emotional triggers, and build on any shifts that happen.
4. Ongoing monitoring: Your care team tracks mood, symptoms, and progress, then adjusts the plan and coordinates care with other providers as needed.

Pricing: With insurance through select partners, plans start at $54 per session and range up to $75 depending on which plan fits your situation. Self-pay pricing runs $83 to $125 per session.

Program outcomes: 69% of participants see a reduction in depression symptoms after 10 weeks. 60% see a reduction in anxiety symptoms. 87% report improvement within four weeks, and the program holds a 4.7 out of 5 average rating.

Ready to find the right path forward? Take the free assessment to see if ketamine therapy could work for you.

Frequently Asked Questions

Does ketamine cause memory loss like ECT?

Not in the same way. Ketamine's main cognitive effect is usually dissociation during the session itself, which typically resolves within hours. At therapeutic doses, memory and cognitive function generally remain stable or improve over the course of treatment. In the ELEKT-D trial, ketamine showed less memory disruption than ECT at the three-week mark. Long-term cognitive data for ketamine is still accumulating, but existing evidence is reassuring.

Can I try ketamine if ECT didn't work for me?

Yes. Because ketamine works through a different brain system than ECT, a lack of response to one doesn't predict failure with the other. Clinical evidence suggests that ketamine and esketamine can be effective even when ECT hasn't been. If you're considering ketamine, Innerwell's free assessment can tell you whether you may be a candidate.

How long do the benefits of each treatment last?

Neither treatment provides permanent remission for most people. A single ketamine dose typically provides relief for about one week, which is why ongoing sessions are part of the standard plan. ECT remission can last longer per course, but follow-up data shows similar relapse rates for both treatments. Continued sessions and therapy are typically recommended with either option.